Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
P/E ratio for Altamira Therapeutics Ltd. (CYTO)
P/E ratio as of 2023: -0.20
According to Altamira Therapeutics Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.20. At the end of 2022 the company had a P/E ratio of -0.15.
P/E ratio history for Altamira Therapeutics Ltd. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.20 |
| 2022 | -0.15 |
| 2021 | -1.26 |
| 2020 | -1.70 |
| 2019 | -1.37 |
| 2018 | -1.24 |
| 2017 | -2.16 |
| 2016 | -2.44 |
| 2015 | -10.63 |
| 2014 | -11.80 |
| 2013 | -12.86 |
| 2012 | -43.09 |
| 2011 | 0.00 |